相关产品推荐更多 >

2-羟基-4-(甲硫基)丁酸钙,4857-44-7,10mM in Water,阿拉丁
¥205.90![4-[2-(2-methylprop-2-enoyloxy)ethoxy]benzoic acid,69260-39-5,≥97%,阿拉丁](https://img1.dxycdn.com/p/s14/2026/0106/352/8465978883691348002.png!wh200)
4-[2-(2-methylprop-2-enoyloxy)ethoxy]benzoic acid,69260-39-5,≥97%,阿拉丁
¥4144.90
tert-butyl (2S,5R)-5-ethyl-2-methyl-piperazine-1-carboxylate,1932079-78-1,≥97%,阿拉丁
¥3456.90![1-羟基-1,3-二氢苯并[c] [1,2]氧杂硼杂环烷-6-羧酸,1221343-14-1,≥95%,阿拉丁](https://img1.dxycdn.com/p/s14/2026/0101/204/2557441706081246002.png!wh200)
1-羟基-1,3-二氢苯并[c] [1,2]氧杂硼杂环烷-6-羧酸,1221343-14-1,≥95%,阿拉丁
¥179.90
NH-双(PEG4-Boc),2182601-75-6,≥98%,阿拉丁
¥1889.90
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
2-8°C储存
- 英文名:
(6R)-5-tert-butoxycarbonyl-5-azaspiro[2.5]octane-6-carboxylic acid
- 库存:
期货
- 供应商:
上海阿拉丁生化科技股份有限公司
- CAS号:
2920197-97-1
- 规格:
T682540-500mg/T682540-250mg/T682540-1g/T682540-100mg
| 规格: | T682540-500mg | 产品价格: | ¥13648.9 |
|---|---|---|---|
| 规格: | T682540-250mg | 产品价格: | ¥8192.9 |
| 规格: | T682540-1g | 产品价格: | ¥20480.9 |
| 规格: | T682540-100mg | 产品价格: | ¥6144.9 |
英文名:(6R)-5-tert-butoxycarbonyl-5-azaspiro[2.5]octane-6-carboxylic acid
纯度或规格:≥97%
SPU:T682540
CAS:2920197-97-1
存储温度:2-8°C储存
运输条件:低温运输
查看阿拉丁官网此产品相关对应页面:
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Hepatitis B virus (HBV) is a major human infectious pathogen. Worldwide, there are more than 350 million chronic carriers of HBV. Sequence divergence within the HBV genome is observed during long-term infection of HBV in patients as a result
十六烷基三甲基铵 dextrorotatory右旋的 electron-pairdonorsite电子队-供体位置 reflux,hea回流/加热 DABCO1,4-diazabicyclo[2.2.2]octane1,4-二氮杂二环[2.2.2]辛烷 DBN1,5-diazabicyclo[4.3.0]non-5-ene1,5-二氮杂二环[4.3.0]壬烯-5 DBPOdibenzoylperoxide过氧
Quantitative Analysis of PRAME for Detection of Minimal Residual Disease in Leukemia
for a 509-amino-acid protein whose function has not yet been identified. PRAME is expressed in various types of cancer, including melanoma (97%), sarcoma (80%), small-cell lung cancer (70%), renal cell carcinoma (40%), and head and neck cancer (29
技术资料暂无技术资料 索取技术资料






